Literature DB >> 1571745

The ability of schizophrenics to perceive and cope with negative affect.

A S Bellack1, K T Mueser, J Wade, S Sayers, R L Morrison.   

Abstract

Thirty-four schizophrenic patients in an acute in-patient hospital were compared with 24 in-patients with major affective disorder and 19 non-patient controls on a role-play test of social skills and a test of affect perception. The role-play test consisted of 12 simulated conversations in which the subject was confronted by parents and friends expressing high-EE criticism or non-critical dissatisfaction. Schizophrenic patients lacked assertiveness and social skills in all conditions, but they did not show any differential impairment when presented with high EE. They consistently lied and denied errors rather than responding assertively or apologizing, whether confronted with high-EE or benign criticisms. On the affect perception test, schizophrenic patients consistently underestimated the intensity or negativeness of negative emotions, but they were not deficient in perception of positive emotional displays. The data do not support the hypothesis that schizophrenic patients are poor at dealing with high-EE behaviours, but do indicate that their ability to cope with even mild negative affect is impaired. Possible explanations for this impairment include limited attentional capacity, a neurologically based perceptual deficit, and a self-protective mechanism to reduce or avoid stress.

Entities:  

Mesh:

Year:  1992        PMID: 1571745     DOI: 10.1192/bjp.160.4.473

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  11 in total

1.  Symptom domains and neurocognitive functioning can help differentiate social cognitive processes in schizophrenia: a meta-analysis.

Authors:  Joseph Ventura; Rachel C Wood; Gerhard S Hellemann
Journal:  Schizophr Bull       Date:  2011-07-15       Impact factor: 9.306

2.  Emotion responsivity, social cognition, and functional outcome in schizophrenia.

Authors:  Jennifer R Mathews; Deanna M Barch
Journal:  J Abnorm Psychol       Date:  2010-02

Review 3.  A biopsychosocial rationale for coerced community treatment in the management of schizophrenia.

Authors:  J L Geller
Journal:  Psychiatr Q       Date:  1995

4.  Neurocognition and social skill in older persons with schizophrenia and major mood disorders: An analysis of gender and diagnosis effects.

Authors:  Kim T Mueser; Sarah I Pratt; Stephen J Bartels; Brent Forester; Rosemarie Wolfe; Corinne Cather
Journal:  J Neurolinguistics       Date:  2010-05       Impact factor: 1.710

5.  Facial emotion perception in schizophrenia: a meta-analytic review.

Authors:  Christian G Kohler; Jeffrey B Walker; Elizabeth A Martin; Kristin M Healey; Paul J Moberg
Journal:  Schizophr Bull       Date:  2009-03-27       Impact factor: 9.306

Review 6.  A review of emotion deficits in schizophrenia.

Authors:  Fabien Trémeau
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

7.  Effect of perceived intimacy on social decision-making in patients with schizophrenia.

Authors:  Sunyoung Park; Jung Eun Shin; Kiwan Han; Yu-Bin Shin; Jae-Jin Kim
Journal:  Front Hum Neurosci       Date:  2014-11-24       Impact factor: 3.169

Review 8.  Violent victimization of adult patients with severe mental illness: a systematic review.

Authors:  Klara Latalova; Dana Kamaradova; Jan Prasko
Journal:  Neuropsychiatr Dis Treat       Date:  2014-10-09       Impact factor: 2.570

9.  Stress load during childhood affects psychopathology in psychiatric patients.

Authors:  Katja Weber; Brigitte Rockstroh; Jens Borgelt; Barbara Awiszus; Tzvetan Popov; Klaus Hoffmann; Klaus Schonauer; Hans Watzl; Karl Pröpster
Journal:  BMC Psychiatry       Date:  2008-07-23       Impact factor: 3.630

10.  Assessment of a six-week computer-based remediation program for social cognition in chronic schizophrenia.

Authors:  Linda K Byrne; Lingyi Pan; Marita McCABE; David Mellor; Yifeng Xu
Journal:  Shanghai Arch Psychiatry       Date:  2015-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.